Navigation Links
Nektar to Announce Financial Results for the Second Quarter of 2013 on Thursday, August 8, 2013, After Close of U.S.-Based Financial Markets
Date:8/1/2013

SAN FRANCISCO, Aug. 1, 2013 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter ended June 30, 2013 on Thursday, August 8, 2013, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT).

The press release and a live audio-only Webcast of the conference call can be accessed through a link that is posted on the home page and Investor Relations section of the Nektar website: http://www.nektar.com. The web broadcast of the conference call will be available for replay through Monday, September 9, 2013.

To access the conference call, follow these instructions:

Dial: (877) 881-2183 (U.S.); (970) 315-0453 (international)
Passcode: 23081302 (Nektar Therapeutics is the host)

In the event that any non-GAAP financial measure is discussed on the conference call that is not described in the press release, or explained on the conference call, related information will be made available on the Investor Relations page at the Nektar website as soon as practical after the conclusion of the conference call.

About Nektar
Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms.  Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for naloxegol (NKTR-118), an investigational drug candidate, which has completed Phase 3 development as a once- daily, oral tablet for the treatment of opioid-induced constipation.  This agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of naloxegol and an opioid.  NKTR-181, a novel mu-opioid analgesic candidate for chronic pain conditions, is in Phase 2 development in osteoarthritis patients with chronic knee pain.  NKTR-192, a novel mu-opioid analgesic in development to treat acute pain is in Phase 1 clinical development.  In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study (the BEACON study) for the treatment of metastatic breast cancer and is also in Phase 2 studies for the treatment of ovarian and colorectal cancers. In anti-infectives, Amikacin Inhale is in Phase 3 studies conducted by Bayer Healthcare to treat patients with Gram-negative pneumonia.

Nektar's technology has enabled eight approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia.  Additional development-stage products that leverage Nektar's proprietary technology platform include Baxter's BAX 855, a long-acting PEGylated rFVIII program, which is in Phase 3 clinical development.

Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India.  Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

Contact: Jennifer Ruddock/Nektar Therapeutics, (415) 482-5585


'/>"/>
SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
3. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
4. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
5. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
6. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
7. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
8. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
9. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
10. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
11. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2016)... 19, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... for the treatment of grievous blood-based disorders with significant ... be presented in a poster session at the European ... Copenhagen . The presentations will include additional ... sickle cell disease (SCD), including 90-day data from a ...
(Date:5/19/2016)... , May 19, 2016  IBM,s (NYSE:   IBM )  ... study to identify drug candidates to cure Zika, a ... declared a global public health emergency. IBM ... with a computer or Android device to join the ... or money to help; they simply  run an app ...
(Date:5/18/2016)... 19, 2016 Global ... Report initially provides a basic overview of ... manufacturing technology, post which the report explores ... the market. Complete report on ... providing 8 company profiles and 98 tables ...
Breaking Medicine Technology:
(Date:5/23/2016)... Angeles, CA (PRWEB) , ... May 23, 2016 ... ... to connecting doctors and patients to provide information about cosmetic procedures, began updating ... now started to rewrite each of their published articles in order to feature ...
(Date:5/23/2016)... , ... May 23, 2016 ... ... security executive networking and relationship-marketing firm, announced today that nominations will be ... Security Executive® (ISE®) Northeast Awards. , Awards include the Information Security Executive® ...
(Date:5/23/2016)... ... May 23, 2016 , ... ... residents of Westchester County for over 24 years, recently hosted its sixth annual ... joined HOW for two remembrance ceremonies, each concluding with the release of Monarch ...
(Date:5/23/2016)... ... May 23, 2016 , ... Overweight and obesity in children can ... the budget, but most of all, it can be hard on the child carrying ... diet food—isn’t making a dint in childhood obesity statistics or making it easier for ...
(Date:5/23/2016)... ... May 23, 2016 , ... A team of cardiovascular surgeons ... the first in the region to use a groundbreaking new technology to provide ... Program partnered with AHN to introduce the technology to the Pittsburgh market. , ...
Breaking Medicine News(10 mins):